Compare Stocks: RCKT, VOR, CVAC, and IMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
IMTX Immatics	$7.43 +0.8%	$8.91	$7.02 ▼ $12.41	$1.02B	1.36	803,552 shs	1.37 million shs
RCKT Rocket Pharmaceuticals	$2.56 -2.7%	$3.31	$2.42 ▼ $5.45	$281.02M	0.5	2.22 million shs	3.37 million shs
VOR Vor Biopharma	$19.90 +4.0%	$21.94	$6.50 ▼ $33.50	$1.18B	1.78	1.36 million shs	1.10 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-14.02%
IMTX Immatics	0.00%	-2.11%	-15.09%	-23.24%	-28.35%
RCKT Rocket Pharmaceuticals	0.00%	0.00%	-26.44%	-34.53%	-24.48%
VOR Vor Biopharma	0.00%	+6.47%	-10.92%	+3.97%	-40.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
IMTX Immatics	$7.43 +0.8%	$8.91	$7.02 ▼ $12.41	$1.02B	1.36	803,552 shs	1.37 million shs
RCKT Rocket Pharmaceuticals	$2.56 -2.7%	$3.31	$2.42 ▼ $5.45	$281.02M	0.5	2.22 million shs	3.37 million shs
VOR Vor Biopharma	$19.90 +4.0%	$21.94	$6.50 ▼ $33.50	$1.18B	1.78	1.36 million shs	1.10 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-14.02%
IMTX Immatics	0.00%	-2.11%	-15.09%	-23.24%	-28.35%
RCKT Rocket Pharmaceuticals	0.00%	0.00%	-26.44%	-34.53%	-24.48%
VOR Vor Biopharma	0.00%	+6.47%	-10.92%	+3.97%	-40.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
IMTX Immatics	2.63	Moderate Buy	$20.60	177.25% Upside
RCKT Rocket Pharmaceuticals	2.42	Hold	$7.77	203.60% Upside
VOR Vor Biopharma	2.90	Moderate Buy	$41.71	109.62% Upside

Current Analyst Ratings Breakdown

Latest RCKT, VOR, CVAC, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$3.00 ➝ $4.00
10/7/2026	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
10/7/2026	RCKT Rocket Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$2.95
10/7/2026	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Perform	$7.00 ➝ $4.00
10/7/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
10/7/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
9/18/2026	IMTX Immatics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/16/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
9/16/2026	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$9.00
9/15/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
9/14/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
IMTX Immatics	$54.60M	18.60	N/A	N/A	$4.09 per share	1.82
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$2.56 per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	11/5/2026 (Estimated)
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest RCKT, VOR, CVAC, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	RCKT Rocket Pharmaceuticals	-$0.39	N/A	N/A	N/A	$0.20 million	N/A
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
IMTX Immatics	N/A	7.54	7.54
RCKT Rocket Pharmaceuticals	0.05	9.24	9.24
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
IMTX Immatics	64.41%
RCKT Rocket Pharmaceuticals	98.39%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
IMTX Immatics	3.30%
RCKT Rocket Pharmaceuticals	21.30%
VOR Vor Biopharma	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
IMTX Immatics	704	136.69 million	132.18 million	Optionable
RCKT Rocket Pharmaceuticals	202	109.78 million	86.39 million	Optionable
VOR Vor Biopharma	76	59.16 million	59.00 million	N/A

RCKT, VOR, CVAC, and IMTX Headlines

Recent News About These Companies

Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus

October 9 at 12:02 PM | uk.finance.yahoo.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026 | globenewswire.com

Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)

October 4, 2026 | finance.yahoo.com

Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened

September 30, 2026 | marketbeat.com

Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | finanznachrichten.de

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | marketscreener.comM

Vor Biopharma en hausse après la publication de résultats encourageants concernant un médicament contre les maladies auto-immunes

September 29, 2026 | boursorama.comB

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | globenewswire.com

Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus

September 29, 2026 | theglobeandmail.com

Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages

September 28, 2026 | marketbeat.com

【VOR】Vor Biopharma

September 23, 2026 | note.comN

Vor Biopharma no fórum Stifel 2026: telitacicept aposta em dupla estratégia

September 23, 2026 | br.investing.com

Vor Biopharma在Stifel 2026论坛上阐述telitacicept双路径布局

September 23, 2026 | cn.investing.com

Vor Biopharma al forum Stifel 2026: telitacicept punta su doppia strategia

September 23, 2026 | it.investing.com

Vor Biopharma en foro Stifel 2026: telitacicept avanza en doble vía

September 23, 2026 | mx.investing.com

Vor Biopharma (NASDAQ:VOR) Shares Down 8.2% - Should You Sell?

September 23, 2026 | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Trading Up 6.1% - Still a Buy?

September 22, 2026 | marketbeat.com

Vor Biopharma: A Funded Replication Story With Franchise Potential

September 18, 2026 | seekingalpha.com

Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance

September 17, 2026 | finance.yahoo.com

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis

September 8, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RCKT, VOR, CVAC, and IMTX Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 10/9/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Immatics NASDAQ:IMTX

$7.43 +0.06 (+0.81%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.42 0.00 (-0.07%)

As of 10/9/2026 07:30 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.56 -0.07 (-2.66%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.58 +0.02 (+0.86%)

As of 10/9/2026 07:56 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Vor Biopharma NASDAQ:VOR

$19.90 +0.77 (+4.03%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$19.90 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCKT, VOR, CVAC, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCKT, VOR, CVAC, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCKT, VOR, CVAC, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RCKT, VOR, CVAC, and IMTX Company Descriptions

CureVac NASDAQ:CVAC

Immatics NASDAQ:IMTX

Rocket Pharmaceuticals NASDAQ:RCKT

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RCKT, VOR, CVAC, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RCKT, VOR, CVAC, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RCKT, VOR, CVAC, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RCKT, VOR, CVAC, and IMTX Company Descriptions

CureVac NASDAQ:CVAC

Immatics NASDAQ:IMTX

Rocket Pharmaceuticals NASDAQ:RCKT

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools